H.C. Wainwright Remains a Buy on HTG Molecular Diagnostics (HTGM)

By Ryan Adsit

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on HTG Molecular Diagnostics (HTGMResearch Report), with a price target of $8. The company’s shares closed yesterday at $1.93, close to its 52-week low of $1.85.

Chen commented:

“Our 12-month price target is based on an estimated market value of the firm at $237M. This includes an asset value at $247M for the HTG EdgeSeq platform, with a 15% discount rate and 0% terminal growth rate, excluding $10M debt.”

According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of -25.6% and a 34.2% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aerpio Pharmaceuticals Inc, Aslan Pharmaceuticals Ltd, and Seelos Therapeutics Inc.

HTG Molecular Diagnostics has an analyst consensus of Strong Buy, with a price target consensus of $6.33.

See today’s analyst top recommended stocks >>

The company has a one-year high of $5.46 and a one-year low of $1.85. Currently, HTG Molecular Diagnostics has an average volume of 240.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. Its customers include biopharmaceutical companies, academic research centers, and molecular testing laboratories. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.